Related Experiment Video
Updated: Jan 9, 2026
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Late pulmonary adverse effects in childhood and adolescent acute lymphoblastic leukaemia survivors: a cross-sectional
Sonja Izquierdo Riis Meyer1,2, Mette Tiedemann Skipper2,3, Birgitte Klug Albertsen2,3
1Department of Paediatrics and Adolescent Medicine, Danish Centre of Paediatric Pulmonology and Allergology, Aarhus University Hospital, Aarhus, Denmark.
Background:
Childhood acute lymphoblastic leukaemia (ALL) survival rates have improved, reaching 95%. However, 25-50% of survivors experience significant treatment-related toxicities. This study investigated late pulmonary adverse effects, including pulmonary symptoms and pulmonary function, in childhood ALL survivors compared to controls.
Methods:
This Danish national cross-sectional study (February 2019 to May 2024) recruited ALL survivors (n=295 eligible) and matched controls 1:1 for pulmonary symptom questionnaire and pulmonary function tests (PFTs): nitrogen multiple breath washout, spirometry, impulse oscillometry, bronchodilator response, diffusing capacity of the lung for carbon monoxide (D LCO) and nitric oxide (D LNO).
Results:
Among 192 survivors and 213 controls performing PFTs, 185 survivors and 209 controls had valid PFTs included in analyses. Prevalences of resting and exertional dyspnoea in survivors (2% and 14%, respectively) versus controls (0% and 3%, respectively) were highest among survivors treated with high-risk chemotherapy (HR) (6% and 18%, respectively) and high-risk chemotherapy followed by stem cell transplantation (HR-SCT) (5% and 26%, respectively). Compared to controls, HR and HR-SCT survivors had impaired mean z-scores for forced expiratory volume in 1 s (-1.64 and -0.37, respectively, versus 0.28), forced vital capacity (-1.66 and -0.67, respectively, versus 0.20), D LNO (-2.39 and -2.55, respectively, versus 0.97) and HR-SCT survivors: lung clearance index (3.31 versus 0.52) and D LCO (-1.23 versus 0.12).
Conclusions:
We found a higher reported prevalence of exertional dyspnoea and impaired pulmonary function in HR and HR-SCT survivors compared to controls. Reassuringly, non-HR/HR-SCT survivors demonstrated pulmonary function comparable to peers. The findings highlight the need for timely detection and tailored monitoring of pulmonary function deficit to improve pulmonary health in HR and HR-SCT survivors.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:17Other Pulmonary Disorders
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:28Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...